Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting-Reference-Cited by-同舟云学术

Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting

Published:2018-03-27 Issue:6 Volume:34 Page:1125-1133
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Wysham Carol H.¹,Pilon Dominic²,Ingham Mike³,Lafeuille Marie-Hélène²,Emond Bruno²,Kamstra Rhiannon²,Pfeifer Michael³,Lefebvre Patrick²

Affiliation:

1. Rockwood Clinic, Spokane, WA, USA;

2. Analysis Group, Inc., Montréal, Québec, Canada;

3. Janssen Scientific Affairs, LLC, Raritan, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2018.1454417

Reference30 articles.

1. National Committee for Quality Assurance (NCQA). Comprehensive diabetes care. Washington, D.C. USA. 2017. Available online at: http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2016-table-of-contents/diabetes-care. Accessed 31 January 2018

2. SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality Objectives in Standardized Quality Management Systems;Quality Management in Health Care;2023-08-30

2. Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world;Primary Care Diabetes;2022-12

3. Quality objectives in management systems – their attributes, establishment and motivational function;International Journal of Quality & Reliability Management;2021-03-12

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice

;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2020-11

5. Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints;Diabetes & Metabolism;2020-09